Abeona Therapeutics Inc ABEO.OQ ABEO.O is expected to show no change in quarterly revenue when it reports results on May 13 (estimated) for the period ending March 31 2025
​LSEG's mean analyst estimate for Abeona Therapeutics Inc is for a loss of 36 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 0.3% in the last three months. ​
Wall Street's median 12-month price target for Abeona Therapeutics Inc is $20.00​, above​ its last closing price of $5.49. ​​​
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.35
-0.35
-0.14
Beat
60.5
Sep. 30 2024
-0.41
-0.40
-0.63
Missed
-55.9
Jun. 30 2024
-0.39
-0.36
0.19
Beat
152.2​
Mar. 31 2024
-0.51
-0.51
-1.16
Missed
-126
​​Dec. 31 2023
-0.47
-0.77
Missed
-63.8
Sep. 30 2023
-0.53
-0.53
-0.48
Beat
8.9​
Jun. 30 2023
-0.71
-0.68
-0.92
Missed
-35.3
Mar. 31 2023
-0.62
-0.58
-0.54
Beat
6.9
This summary was machine generated May 9 at 15:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)